Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Market Opened: Jan 24, 2022, 7:00 PM ET
Volume
$29,057End Date
Apr 1, 2022Market Opened
Jan 24, 2022, 7:00 PM ETOutcome proposed: No
No dispute
Final outcome: No
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057End Date
Apr 1, 2022Market Opened
Jan 24, 2022, 7:00 PM ETOutcome proposed: No
No dispute
Final outcome: No




Beware of external links.
Beware of external links.
Frequently Asked Questions